Oxidative stress and inflammation in chronic kidney disease: Role of intravenous iron and vitamin D

Journal of Pharmacy Practice

Volumn 21, Issue 3, 2008, Pages 214-224

  Pai, Amy Barton ^a   Conner, Todd A ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Chronic kidney disease; Inflammation; Intravenous iron; Oxidative stress; Vitamin D

Indexed keywords

ALPHA TOCOPHEROL; CALCITRIOL; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARICALCITOL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SELENIUM; VITAMIN D DERIVATIVE;

ALLERGIC REACTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DNA DAMAGE; DRUG MECHANISM; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON THERAPY; KIDNEY FAILURE; LIPID PEROXIDATION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; VITAMIN D DEFICIENCY;

EID: 45449088544     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008316288     Document Type: Review

References (90)

1. United States Renal Data Systems (USRDS). 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases ; 2006.
2. Foley RN, Parfrey PS, Sarnak MJ Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 ; 32 (5 suppl 3). S112 - S119.
3. Baber U., Toto RD, de Lemos JA Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal disease. Am Heart J. 2007 ; 153: 471-477.
4. Yao Q., Pecoits-Filho R., Lindholm B., Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scan J Urol Nephrol. 2004 ; 38: 405-416.
5. Himmelfarb J., Stenvinkel P., Ikizler TA, Hakim RM The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002 ; 62 (5). 1524-1538.
6. Ridker PM, Cushman M., Stamfer MJ, Tracy RP, Hennekens CH Inflammation aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med. 1997 ; 336: 973-979.
7. Ridker PM, Buring JE, Shih J., Matias M., Hennekens C. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 ; 98: 731-733.
8. Zimmerman J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 ; 55: 648-658.
9. Tripepi G., et al. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. JASN. 2005 ; 16: S83 - S88.
10. Owen WF C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998 ; 54: 627-636.
11. Samouilidou EC, et al. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol. 2003 ; 35: 393-397.
12. Pupim LB, et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004 ; 65: 2371-2379.
13. Shoji T., Fukumoto M., Kimoto E., et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int. 2002 ; 62: 2230-2237.
14. Raj DSC, Dominic EA, Pai A., Osman F., Morgan M., Pickett G., Shah VO, Ferrando A., Moseley P. Skeletal muscle, cytokines and oxidative stress in end-stage renal disease. Kidney Int. 2005 ; 68: 2338-2344.
15. Salahudeen AK, Oliver B., Bower JD, Roberts LJ Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 ; 60: 1525-1531.
16. Martinet W., De Meyer GRY, Herman AG, Kockx MM Reactive oxygen species induce RNA damage in human atherosclerosis. Eur J Clin Invest. 2004 ; 34: 323-327.
17. Martinet W., Knaapen MWM, De Meyer GRY, Herman AG, Kockx MM Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002 ; 106: 927-932.
18. Steinvinkel P., Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dial. 2002 ; 15: 329-337.
19. Steinvinkel P., Heimburger O., Jogestrand T. Elevated interleukin-6 predicts progressive atherosclerosis in dialysis patients: association to Clamydia pneumoniae positivity. Am J Kidney Dis. 2002 ; 39: 274-282.
20. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D., Stenzel KH, Rubin AL Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998 ; 32: 107-114.
21. Rao M., Guo D., Perianayagam M., Tighiouart H., Jaber B., Pereira BJG, Balakrishnan VS Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005 ; 45: 324-333.
22. Morena M., Cristol JP, Bosc JY, Tetta C., Forret G., Leger CL, Delcourt C., Papoz L., Descomps B., Canaud B. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transpl. 2002 ; 17 (3). 422-427.
23. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R., Homel P., Levin NW Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis. 2001 ; 38: 1408-1413.
24. Keaney JF Jr, Loscalzo J. Diabetes, oxidative stress and platelet aggregation. Circulation. 1999 ; 99: 189-191.
25. Eiselt J., Racek J., Opatrny K. Jr. Oxidative stress: the effect of erythropoietin and the dialysis membrane. Int J Artif Organs. 2000 ; 23 (1). 33-40.
26. Dasgupta A., Hussain S., Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron. 1992 ; 60: 56-59.
27. Teng M., Wolf M., Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005 ; 16 (4). 1115-1125.
28. Tentori F., Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006 ; 70 (10). 1858-1865.
29. Andress D. Nonclassical aspects of differential Vitamin D receptor activation. Drugs. 2007 ; 67 (14) 1999-2012.
30. Fishbane S., Ungureanu V., Maesaka, Kaupke CJ, Lim V., Wish J. The safety of intravenous iron dextran in hemodialysis patients. 1996 ;28: 529-534.
31. Feldman HI, Joffe M., Robinson B., Knauss J., Cizman B., Guo W., Franklin-Becker E., Faich G. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004 ; 151: 623-1632.
32. Yoshimura K., Nakano H., Yokoyama K., Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clin Exp Nephrol. 2005 ; 9: 158-163.
33. National Kidney Foundation (NKF) K/DOQI Guidelines. K/DOQI Clinical Practice Recommendations for Anemia of Chronic Kidney Disease. http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index. htm. Accessed November 1, 2007.
34. Spinowitz B., Schwenk M., Jacobs P., Bolton W., Kaplan MR, Charytan C., Galler M. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int. 2005 ; 68: 1801-1807.
35. Lewis JM, Jacobs PM, Frigo TB Comparison of free iron in fermoxytol with current iron therapeutics. J Am Soc Nephrol. 2003 ; 14: 771A.
36. Sunder-Plassman,, Horl WH Comparative look at intravenous iron agents: pharmacology, efficacy and safety of iron dextran, iron saccharate, and ferric gluconate. Semin Dial. 1999 ; 12: 243-248.
37. Siverberg DS, Blum M., Peer G., Kaplan E., Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron. 1996 ; 72: 413-417.
38. Faich G., Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Diseases. 1999 ; 33 (3) 464-470.
39. Van Wyck DB, Cavallo G., Spinowitz BS, Adhikarla R., Gagnon S., Charytan C., Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American trial. Am J Kidney Dis. 2000 ; 36: 88-97.
40. Parkkinen J., von Bonsdorff L., Peltonen S., Gronhagen-Riska C., Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after iv iron-saccharate administration. Nephrol Dial Trans. 2000 ; 15: 1827-1834.
41. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transpl. 1999 ; 14: 2680-2687.
42. Roob JM, Khoschsorur G., Tiran A., Horina JH, Holzer H., Winklhofer-Roob BM Vitamin E attenuates oxidative stress induced by intravenous iron in patients in hemodialysis. 2000 ;11: 539-549.
43. Mimic-Oka J., Savic-Radojevic A., Pljesa-Ercegovac M., Opacic M., Simic T. Evaluation of oxidative stress after repeated intravenous iron supplementation. Renal Fail. 2005 ; 27: 345-351.
44. Maruyama Y., Nakayama M., Yoshimura K., Nakano H., Yamamoto H., Yokoyama K., Lindholm B. Effects of repeated intravenous iron administration in hemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Nephrol Dial Transpl. 2007 ; 22: 1407-1412.
45. Danielson BG Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004 ; 15 (suppl 2). S93-98.
46. De Vecchi A., Novembrino C., Lonati S., Ippolito S., Bamonti F. Two different modalities of iron gluconate iv administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. Nephrol Dial Transpl. 2007 ; 22: 1709-1713.
47. Malindretos P., Sarafidis P., Rudenco I., Raptis V., Makedou K., Makedou A., Grekas D. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol. 2007 ; 27 (6). 572-579.
48. Zheng H., Huang X., Zhang Q., Katz SD Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int. 2006 ; 69: 679-684.
49. Zager RA, Johnson ACM, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002 ; 40 (1). 90-103.
50. Zager RA, Johnson ACM, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNFα mRNA production and TNF-α release. Kidney Int. 2005 ; 288: F290 - F297.
51. Pai AB, Harford A., Boyd A., McQuade C., Zager P. Comparison of oxidative stress markers in hemodialysis (HD) patients receiving iron dextran (ID), sodium ferric gluconate (SFG) and iron sucrose (IS). Pharmacotherapy. 2007 ; 27: 343-350.
52. Van Campenhout A., Van Campenhout C., Lagrou A., Maneul-y-Kennoy B. Iron-induced oxidative stress in hemodialysis patients a pilot study on the impact of diabetes. Biometals. 2007 Jun 22 [Epub ahead of print].
53. Ardalan M., Tubbs RS, Shoja MM Vitamin E and selenium co-supplementation attenuates oxidative stress in hemodialysis patients receiving intra-dialysis iron infusion. Nephrol Dial Transpl. 2007 ; 22: 973-974.
54. Hujairi NMA, Afzali B., Goldsmith DJA. Cardiac calcification in renal patients: what we do and don't know. Am J Kidney Dis. 2004 ; 43: 234-243.
55. Gonzalez EA, Sachdeva A., Oliver D. Vitamin D deficiency in chronic kidney disease. Am J Nephrol. 2004 ; 24: 503-510.
56. National Kidney Foundation (NKF). K/DOQI Guidelines. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. http://www.kidney.org/professionals/kdoqi/guidelines_bo ne/index.htm. Accessed November 1, 2007.
57. Dusso AS, Thadhani R., Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol. 2004 ; 24 (1). 10-16.
58. Slatopolsky E., Dusso A., Brown A. New analogs of vitamin D3. Kidney Int. 1999 ; 56: S46-51.
59. Takahashi F., Finch JL, Denda M., Dusso A., Brown A., Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-Nor1,25-(OH)2D2, supresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis. 1997 ; 30 (1). 105-112.
60. LLach F., Keshav G., Goldblat M., Lindberg J., Sadler R., Delmez J., Arruda J., Lau A., Slatopolsky E. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-Nor-1,25- dihydroxyvitamin D2. Am J Kidney Dis. 1998 ; 32 (suppl 2). S48-54.
61. Shoji T., Shinohara K., Kimoto E. Lower risk for cardiovascular mortality in oral 1-α-hydroxy vitamin D3 users in a hemodialysis population. Nephrol Dial Transpl. 2004 ; 19: 179-184.
62. Zager RA Calcitriol directly sensitizes renal tubular cells to ATP-depletion-and iron-mediated attack. Am J Pathol. 1999 ; 154: 1899-1909.
63. Dobrez DG, Mathes A., Amdahl M., et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transpl. 2004 ; 19: 1174-1181.
64. Teng M., Wolf M., Lowrie M., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003 ; 349: 446-456.
65. Li YC, Kong J., Wei M., et al. 1,25 dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002 ; 110: 229-238.
66. Mathieu C., Adorini L. The coming of age of 1,25 dihydroxyvitamin D3 as immunomodulatory agents. Trends Mol Med. 2002 ; 4: 174-179.
67. Kitagawa S., Yamaguchi Y., Kunitomo M., Imaizumi N., Fujiwara M. Altered vasoconstrictor responsiveness in vitamin D-induced arteriosclerotic rat aortas. Jpn J Pharmacol. 1993 ; 61: 283-289.
68. Weishaar RE, Simpson RU The involvement of the endocrine system in regulating cardiovascular function emphasis on vitamin D3. Endocr Rev. 1989 ; 10: 351-365.
69. Kong J., Li YC Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol. 2003 ; 285: 255-261.
70. O' Connell TD, Berry JE, Jarvis AK, et al. 1,25 dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol Heart Circ Physiol. 1997 ; 272: H1751-1758.
71. Chen S., Wu J., Hsieh JC, et al. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension. 1998 ; 31: 1338-1342.
72. Wu J., Garami M., Cao L. et al. 1,25-(OH)2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am J Physiol Endocrinol Metab. 1995 ; 268: E108-113.
73. Wu J., Garami M., Cheng T., et al. 1,25-(OH)2 vitamin D3 and retinoic antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996 ; 97: 1577-1588.
74. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005 ; 288: E125 - E132.
75. Zittermann A., Schleithoff SS, Tenderich G., Berthold HK, Korfer R., Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure ? J Am Coll Cardiol. 2003 ; 41: 105-112.
76. McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron. 1984 ; 36: 94-100.
77. Lemmila S., Saha H., Virtanen V., Ala-Houhala I., Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol. 1998 ; 18: 404-410.
78. Wiseman H. Vitamin D is a membrane antioxidant. FEBS. 1993 ; 326: 285-288.
79. Crivello JF Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch Biochem Biophys. 1988 ; 262: 471-480.
80. Ibi M., Sawada H., Nakanishi M., Kume T., Katsuki H., Kaneko S., Shimohama S., Akaike A. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001 ; 40: 761-771.
81. Meister A. Glutathione metabolism and its selective modification. J Biol Chem. 1988 ; 263: 17206-17208.
82. Chaterjee M. Vitamin D and genomic stability. Mut Res. 2001 ; 475: 69-88.
83. Eiserich JP, Baldus S., Brennan ML et al. Myeloperoxidase, a leukocyte derived vascular NO oxidase. Science. 2002 ; 296 ; 2391
84. Himmelfarb J., McMenamin E., Loseto G., et al. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 2001 ; 31: 163.
85. Martinesi M., Bruni S., Stio M., et al. 1,25 dihydroxyvitamin D3 inhibits tumor necrosis factor-α -induced adhesion molecule expression in endothelial cells. Cell Biol Int. 2006 ; 30: 365.
86. Weinreich T., Wuthrich RP, Booy C., et al. Suppression of ICAM-1 expression in renal proximal tubule cells by 1,25 dihydroxyvitamin D3. Kidney Blood Press Res. 2001 ; 24: 92.
87. Giulietti A., van Etten E., Overbergh L., et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile 1,25 dihydroxyvitamin D3 works as an anti-inflammatory. Diabetes Res Clin Pract. 2006 ; 77 (1). 47-57.
88. Wu-Wong J., Nakane M., Ma J. Vitamin D analogs modulate expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. 2007 ;44: 11-18.
89. Hirata, M., Makibayashi, K., Katsumata, K., et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant. 2002 ; 17: 2132-2137.
90. Agarwal R., Acharya M., Tian J., Hippensteel RL, Melnick sJZ, Qiu P., Williams L., Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005 ; 68 (6). 2823-2828.